Literature DB >> 21242707

Galanin receptor antagonist m35 but not m40 or c7 ameliorates cerulein-induced acute pancreatitis in mice.

M Bhandari1, M Kawamoto, A C Thomas, S G Barreto, A C Schloithe, C J Carati, J Toouli, G T P Saccone.   

Abstract

BACKGROUND/AIMS: We compared the galanin antagonists C7, M35, M40 and galantide, for their ability to ameliorate acute pancreatitis (AP).
METHODS: Galanin antagonists were co-administered with 7 hourly cerulein injections used to induce AP. Plasma amylase and lipase activities were measured as indices of AP, and pancreata were harvested at 12 h for histological examination and estimation of myeloperoxidase (MPO) activity.
RESULTS: Treatment with galantide, M35 and C7 ameliorated the AP-induced plasma hyperenzymemia by 40-75%. Administration of M40 did not significantly alter plasma hyperenzymemia. Galantide, M35 and M40 significantly reduced the pancreatic MPO activity by 65-80%, whereas C7 increased MPO activity. Galantide and M35 but not C7 or M40 treatment significantly reduced the AP-induced necrosis score by 30-50% compared to the AP alone group. C7 alone increased plasma lipase activity and the pancreatic necrosis score compared with saline treatment alone, whereas the other antagonists were without effect.
CONCLUSION: Galantide and M35 ameliorated the severity of AP, but M40 and C7 had mixed effects. Complex galanin pathways may be involved in cerulein-induced AP. M35 and galantide are potential therapeutic peptides for the treatment of AP and further evaluation should be considered. and IAP.
Copyright © 2011 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21242707     DOI: 10.1159/000314603

Source DB:  PubMed          Journal:  Pancreatology        ISSN: 1424-3903            Impact factor:   3.996


  3 in total

Review 1.  Neuropeptide receptors as potential drug targets in the treatment of inflammatory conditions.

Authors:  Erika Pintér; Gábor Pozsgai; Zsófia Hajna; Zsuzsanna Helyes; János Szolcsányi
Journal:  Br J Clin Pharmacol       Date:  2014-01       Impact factor: 4.335

2.  Octreotide negates the benefit of galantide when used in the treatment of caerulein-induced acute pancreatitis in mice.

Authors:  Savio G Barreto; Colin J Carati; Ann C Schloithe; James Toouli; Gino T P Saccone
Journal:  HPB (Oxford)       Date:  2010-08       Impact factor: 3.647

3.  Alarin alleviated cardiac fibrosis via attenuating oxidative stress in heart failure rats.

Authors:  Jinshuang Li; Hao Ding; Yong Li; Hao Zhou; Wanhong Wang; Yong Mei; Ronglin Zhang
Journal:  Amino Acids       Date:  2021-06-05       Impact factor: 3.520

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.